Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms restricting hepatitis B virus cross-species transmission.

mBio·2026
Same author

Metadomain and metaloop genome interactions in mammalian T cells.

Cell reports·2026
Same author

EIF4H and YBX1 are essential host factors for hepatitis E virus replication and pathogenesis.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Metadomain and metaloop genome interactions in mammalian T cells.

bioRxiv : the preprint server for biology·2025
Same author

Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells.

PLoS pathogens·2025
Same author

Assessment of hepatitis C virus permissiveness in iteratively genetically humanized mice.

Journal of virology·2025

Related Experiment Video

Updated: Jun 19, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Towards a small animal model for hepatitis C.

Alexander Ploss1, Charles M Rice

  • 1Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York 10065, USA. aploss@rockefeller.edu

EMBO Reports
|October 17, 2009
PubMed
Summary
This summary is machine-generated.

Developing a mouse model for Hepatitis C virus (HCV) infection is crucial for advancing antiviral drug development. This research explores strategies to overcome species barriers, enabling new therapeutic research for this chronic liver disease.

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jun 19, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

  • Virology
  • Hepatology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) causes chronic liver disease, affecting 3% of the global population.
  • Current prevention and treatment options for HCV are limited, with no vaccine available and interferon-based therapies often ineffective and causing side effects.

Purpose of the Study:

  • To discuss the prospects of developing a small-animal model for HCV infection, specifically a mouse model.
  • To facilitate the development and preclinical testing of antiviral compounds.
  • To enable further research into the mechanisms of viral pathogenesis.

Main Methods:

  • Reviewing recent findings on HCV entry and replication mechanisms.
  • Considering advancements in xenotransplantation biology.
  • Highlighting three distinct approaches to overcome species tropism barriers.

Main Results:

  • The natural tropism of HCV is restricted to humans and chimpanzees, posing a significant challenge for small-animal model development.
  • Recent progress in understanding HCV entry and replication provides a basis for developing alternative models.
  • Xenotransplantation offers potential avenues for creating a functional HCV model in mice.

Conclusions:

  • Developing a mouse model for HCV infection is a critical unmet need for advancing antiviral research.
  • Combining insights into viral mechanisms with xenotransplantation techniques presents promising strategies.
  • Successful development of such a model would significantly accelerate the discovery of new HCV therapies.